{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of January 2023): No"],"condition":["Ovarian Cancer","Triple Negative Breast Neoplasms","Gastric Cancer","Colorectal Cancer","Triple Negative Breast Cancer"],"disease":["Ovarian Cancer","Triple Negative Breast Neoplasms","Gastric Cancer","Colorectal Cancer","Triple Negative Breast Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2741380"],"location":["United States"],"study_start_month":["8"],"keyword":["Irinotecan","Paclitaxel","Navicixizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors","description":"This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts:\n* Cohort A: CRC\n* Cohort B: Gastric and GEJ cancer\n* Cohort C: TNBC\n* Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)","dates":{"creation":"2022-08-15"},"accession":"2741380","cross_references":{"ClinicalTrials___gov":["NCT05453825"]}}